Answers are grounded in this paper and cite their sources.
Randomized trial shows reduced risks of CKD progression and cardiovascular events in patients with type 2 diabetes, suggesting finerenone's potential benefits.
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).
No takes yet. Share an insight, caveat, or question.
Bakris et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: